CAGT hero 2

Leading in the Development and Application of Genomic Technologies

Realizing the promise of the Genomic Revolution requires a quantum leap in the mechanistic understanding of disease biology and the discovery of drug targets. Remarkable recent innovations such as CRISPR-based genome editing, next-generation DNA sequencing, and high-throughput single-cell genomics have illuminated the path by which a technology-driven approach can inform, streamline, and accelerate drug target discovery. However, a cohesive effort is essentail to assimilate these otherwise disparate technologies and disease areas.

The Center for Advanced Genomic Technologies has assembled a team of world-leading engineers, scientists, and physicians to integrate these technologies, adapt them to help unravel disease biology, and discover new drug targets to catalyze a more robust biotechnology enterprise.

In the News

October 14, 2019 | Duke GCB News

Weapon of Mass Congestion: Protection from Influenza Virus through Gene Control

DARPA recently awarded a grant to a Duke team for a multifaceted research effort aimed at temporarily regulating gene expression using RNA-based techniques that could help protect against pandemic flu by boosting lung resistance to the virus, attacking the virus directly, enhancing the immune system response and improving the effects of existing vaccines.

The Duke Center for Advanced Genomic Technologies aims to investigate and re-engineer the inner workings of cellular gene regulation machinery and networks

September 30, 2019 | Duke Engineering News

New Duke Center Takes Aim at the Dark Genome

Spanning Duke University and Duke Health, the Center for Advanced Genomic Technologies will use homegrown tools and techniques to discover potential therapies for human diseases from autism to cancer to schizophrenia

ILLUSTRATIONS REPRESENTING THE COMPONENTS OF THE COMMON DCAS9 SYSTEM (TOP) AND THE CASCADE SYSTEM (BOTTOM)

September 23, 2019 | Duke Engineering News

New CRISPR Class Expands Genetic Engineering Toolbox

In a recent study, Charles Gersbach and Adrian Oliver, a post-doctoral fellow in the Gersbach lab who led the project, describe how they successfully harnessed Class 1 CRISPR systems to turn target genes on and off and edit the epigenome in human cells for the first time.